Stockreport

Takeda Continues Divestiture Strategy with Sale of Select OTC and Non-Core Assets in Europe to Orifarm for Up to Approximately $670M USD

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF Portfolio includes select OTC and prescription products and two manufacturing facilitiesTransaction further accelerates Company’s deleveraging plan OSAKA, Japan--(BUS [Read more]